You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 66 No. 10, October 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •eSupplement
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Cognitive Disorders
 •Psychiatry
 •Schizophrenia
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Influence of NOS1 on Verbal Intelligence and Working Memory in Both Patients With Schizophrenia and Healthy Control Subjects

Gary Donohoe, DClinPsych, PhD; James Walters, MRCPsych, BM; Derek W. Morris, PhD; Emma M. Quinn, MSc; Róisín Judge, BA; Nadine Norton, PhD; Ina Giegling, PhD; Annette M. Hartmann, PhD; Hans-Jürgen Möller, MD; Pierandrea Muglia, MD; Hywel Williams, PhD; Valentina Moskvina, PhD; Rosemary Peel, MSc; Therese O’Donoghue, MSc; Michael J. Owen, FRCPsych, PhD; Michael C. O’Donovan, FRCPsych, PhD; Michael Gill, MRCPsych, MD; Dan Rujescu, MD; Aiden Corvin, MRCPsych, PhD

Arch Gen Psychiatry. 2009;66(10):1045-1054.

Context  Human and animal studies have implicated the gene NOS1 in both cognition and schizophrenia susceptibility.

Objective  To investigate whether a potential schizophrenia risk single-nucleotide polymorphism (rs6490121) identified in a recent genome-wide association study negatively influences cognition in patients with schizophrenia and healthy control subjects.

Design  A comparison of both cases and controls grouped according to NOS1 genotype (GG vs AG vs AA) on selected measures of cognition in 2 independent samples. We tested for association between NOS1 rs6490121 and cognitive functions known to be impaired in schizophrenia (IQ, episodic memory, working memory, and attentional control) in an Irish sample. We then sought to replicate the significant results in a German sample.

Setting  Unrelated patients from general adult psychiatric inpatient and outpatient services and unrelated healthy volunteers from the general population were ascertained.

Participants  Patients with DSM-IV–diagnosed schizophrenia and healthy control subjects from independent samples of Irish (cases, n = 349; controls, n = 230) and German (cases, n = 232; controls, n = 1344) nationality.

Results  A main effect of NOS1 genotype on verbal IQ and working memory was observed in the Irish sample where the homozygous carriers of the schizophrenia risk G allele performed poorly compared with the other genotype groups. These findings were replicated in the German sample, again with the GG genotype carriers performing below other genotype groups. Post hoc analysis of additional IQ measures (full-scale and performance IQ) in the German sample revealed that NOS1 GG carriers underperformed on these measures also.

Conclusions  NOS1 is associated with clinically significant variation in cognition. Whether this is a mechanism by which schizophrenia risk is increased (eg, via an influence on cognitive reserve) is yet to be confirmed.


Author Affiliations: Neuropsychiatric Genetics Research Group, Department of Psychiatry and Institute of Molecular Medicine (Drs Donohoe, Morris, Gill, and Corvin and Mss Quinn, Judge, Peel, and O’Donoghue) and Trinity Institute of Neuroscience (Drs Donohoe, Gill, and Corvin and Ms O’Donoghue), Trinity College Dublin, Dublin, Ireland; Department of Psychological Medicine, School of Medicine, Cardiff University, Cardiff, Wales (Drs Walters, Norton, Williams, Moskvina, Owen, and O’Donovan); Division of Molecular and Clinical Neurobiology, Department of Psychiatry (Drs Giegling, Hartmann, and Rujescu) and Department of Psychiatry (Dr Möller), Ludwig-Maximilians-Universität, Munich, Germany; and Medical Genetics, Research & Development, GlaxoSmithKline, Verona, Italy (Dr Muglia).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(10):1043.
FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.